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Chemotherapy-Induced Peripheral Neuropathy (CIPN) is the most frequent adverse effect of pharma-
cological cancer treatments. The occurrence of neuropathy prevents the administration of fully-effective
drug regimen, affects negatively the quality of life of patients, and may lead to therapy discontinuation.
CIPN is currently treated with anticonvulsants, antidepressants, opioids and non-opioid analgesics, all of
which are flawed by insufficient anti-hyperalgesic efficacy or addictive potential. Understandably,
developing new drugs targeting CIPN-specific pathogenic mechanisms would dramatically improve ef-
ficacy and tolerability of anti-neuropathic therapies. Neuropathies are associated to aberrant excitability
of DRG neurons due to the alteration in the expression or function of a variety of ion channels. In this
regard, Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels are overexpressed in in-
flammatory and neuropathic pain states, and HCN blockers have been shown to reduce neuronal
excitability and to ameliorate painful states in animal models. However, HCN channels are critical in
cardiac action potential, and HCN blockers used so far in pre-clinical models do not discriminate between
cardiac and non-cardiac HCN isoforms. In this work, we show an HCN current gain of function in DRG
neurons from oxaliplatin-treated rats. Biochemically, we observed a downregulation of HCN2 expression
and an upregulation of the HCN regulatory beta-subunit MirP1. Finally, we report the efficacy of the
selective HCN1 inhibitor MEL57A in reducing hyperalgesia and allodynia in oxaliplatin-treated rats
without cardiac effects. In conclusion, this study strengthens the evidence for a disease-specific role of
HCN1 in CIPN, and proposes HCN1-selective inhibitors as new-generation pain medications with the
desired efficacy and safety profile.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
1.1. Clinical aspects of CIPN
Chemotherapy-induced peripheral neuropathy (CIPN) is a pro-
gressive, long-lasting condition characterized by numbness, dys-
esthesia, hyperalgesia and allodynia (Addington and Freimer, 2016;Avan et al., 2015). It is estimated that up to 90% of all cancer patients
receiving chemotherapy will be affected by CIPN at various severity
levels (Bokhari and Sawatzky, 2009). Pain intensity in patients
experiencing CIPN is distressing and debilitating and could lead to
treatment discontinuation with obvious consequences on clinical
outcome (Kim et al., 2015). Due to the lack of specific therapies,
CIPN is treated with the same therapeutic approaches employed in
other chronic pain states. First-line treatments include voltage-
gated calcium channel alpha-2-delta blockers, tricyclic antide-
pressants, selective serotonin and norepinephrine reuptake in-
hibitors and local anesthetics. Opioid analgesics represent second-
line therapies, while third-line therapies include other
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antagonists, and topical agents (Kim et al., 2015). These classes of
drugs often have severe side effects when used chronically. More-
over, none of these drugs is fully effective in the prevention or
treatment of CIPN (Cavaletti, 2014; Roberts et al., 1997). The in-
adequacy of CIPN therapy is due to incomplete comprehension of
the alterations triggered by the chemotherapeutic and affecting the
excitability of peripheral sensory neurons, in which neuropathies
are believed to arise. Identifying CIPN-specific disease pathways
would dramatically improve our chances to develop specific phar-
macological tools with higher efficacy and tolerability.
1.2. HCN channels in pain transmission
In the past decade, it has been demonstrated that HCN channels,
mediating the Hyperpolarization-activated current (Ih), have a
prominent role in controlling the excitability of nociceptive neu-
rons and, therefore, in driving peripheral pain transmission
(Momin et al., 2008; Emery et al., 2011; Young et al., 2014; Resta
et al., 2016). In this respect, the efficacy of HCN blockers has been
demonstrated in various neuropathic pain models (Dalle and
Eisenach, 2005; Jiang et al., 2008; Takasu et al., 2010), suggesting
a prominent role of these channels in maintaining chronic pain
state. In 2011, Descoeur and collaborators reported an increase in
HCN1 mRNA levels in DRG from oxaliplatin (OXA)-treated mice.
They also demonstrated that ivabradine (IVA), a commercial HCN
blocker (Berdeaux et al., 2009), reduces OXA-induced hyperalgesia
and cold allodynia (Descoeur et al., 2011). Similar results were
obtained by Young and collaborators (Young et al., 2014). Although
strongly suggesting a prominent role for HCN channels in OXA-
induced neuropathy, these studies lack to demonstrate the nature
of the alterations undergone by HCN channels following chronic
exposure to platinum compounds, i.e., whether a change in the
expression pattern of HCN isoforms takes place, or, rather, their
biophysical properties are affected. In a translation perspective, the
anti-hyperalgesic potential of “pan” HCN blockers (i.e., not
discriminating among HCN isoforms) cannot be fully exploited due
to the detrimental effect that block of HCN4 in the sinus atrial node
may have on cardiac rhythm (Novella Romanelli et al., 2016;
Sartiani et al., 2017; Stillitano et al., 2013) In this work, we
demonstrate that nociceptor neurons from OXA-treated rats show
significant Ih gain of function in ex vivo recordings. Biochemically,
we observed downregulation of HCN2 protein and upregulation of
the HCN channels ancillary b-subunit Mink Related Peptide1
(MiRP1), known to increase the open probability of HCN1. In
addition, we report the efficacy of the selective HCN1 inhibitor
MEL57A in reducing hyperalgesia in CIPN-expressing rats without
effects on cardiac rhythm. In conclusion, this study strengthens the
evidence for a disease-specific role of HCN1 in CIPN, and proposes
HCN1-selective inhibitors as new-generation pain medications
with the desired efficacy and safety profile.
2. Methods
2.1. Animals
Two-month old male Wistar rats (Envigo, Varese, Italy),
approximately 220e250 g at the beginning of the experimental
procedure, were used for all experiments. Animals were housed at
CeSAL (Centro Stabulazione Animali da Laboratorio, University of
Florence) and used at least one week after their arrival. Four rats
were housed per cage (size 26 41 cm) kept at 23± 1 C with a 12-
h light/dark cycle (light on at 7 a.m.). Animals were fed a standard
laboratory diet and had access to tap water ad libitum. All animal
manipulations were carried out according to the Directive 2010/63/EU of the European parliament and of the European Union council
(22 September 2010) on the protection of animals used for scientific
purposes. The ethical policy of the University of Florence complies
with the Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-01). Formal
approval to conduct the experiments described was obtained from
the Animal Subjects Review Board of the University of Florence.
Experiments involving animals have been reported according to
ARRIVE guidelines (McGrath and Lilley, 2015). All efforts were
made to minimize animal suffering and to reduce the number of
animals used.2.2. OXA neuropathic pain model
Rats were treated with OXA (2.4mg/kg), administered intra-
peritoneally (i.p.) for 5 consecutive days every week for 2 weeks (10
i.p. injections) (Cavaletti et al., 2001). OXA was dissolved in 5%
glucose solution. Control animals received an equivalent volume of
5% glucose i.p. (vehicle).2.3. Administration of HCN blockers
4-Ethylphenylamino-1,2-dimethyl-6-
methylaminopyrimidinium chloride (ZD7288) (1e10mg/kg; Toc-
ris) and IVA (0.1e5mg/kg; Sigma-Aldrich) were dissolved in saline
solution and administered i.p and s.c, respectively. MEL57A
(0.1e10mg/kg) was suspended in 1% carboxymethylcellulose so-
dium salt (CMC) and p.o administered. All acute treatments started
15 days from the beginning of OXA injections.2.4. Paw pressure test
The nociceptive threshold was determined with an analgesim-
eter (Ugo Basile, Varese, Italy) as previously described (Di Cesare
Mannelli et al., 2017). Briefly, a constantly increasing pressure
was applied to a small area of the dorsal surface of the hind paw
using a blunt conical mechanical probe. Mechanical pressure was
increased until vocalization or a withdrawal reflex occurred while
rats were lightly restrained. Thresholds were expressed in grams.
Rats scoring below 40 g or over 75 g during the test before drug
administration (25%) were rejected. An arbitrary cut-off value of
100 gwas adopted. The datawere collected by an observerwhowas
blinded to the protocol.2.5. von Frey test
The animals were placed in 20 20 cm Plexiglas boxes equip-
ped with a metallic meshy floor, 20 cm above the bench. A habit-
uation of 15minwas allowed before the test. An electronic von Frey
hair unit (Ugo Basile, Varese, Italy) was used, and the withdrawal
threshold was evaluated by applying force ranging from 0 to 50 g
with a 0.2 g accuracy. Punctuate stimulus was delivered to the mid-
plantar area of each anterior paw from below the meshy floor
through a plastic tip and the withdrawal threshold was automati-
cally displayed on the screen. Paw sensitivity threshold was defined
as the minimum pressure required to elicit a robust and immediate
withdrawal reflex of the paw. Voluntary movements associated
with locomotion were not taken as a withdrawal response. Stimuli
were applied on each anterior paw with an interval of 5 s. The
measurement was repeated 5 times and the final value was ob-
tained by averaging the 5 measurements (Sakurai et al., 2009).
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The Hargreaves radiant heat method was carried out as
demonstrated by (Tao et al., 2004). The rats were placed individ-
ually in clear plastic chambers of Ugo Basile plantar test apparatus
for 20min prior to the experiment for adaptation. Heat stimulation
was applied at IR 60 (infrared intensity 50) on the paw with a 30-s
cut-off time. The paw withdrawal latency comprised the time from
the start of the beam light until the animal withdrew the paw from
the heat stimulus (reaction time) was measured.
2.7. DRG neurons culture
Rat dorsal root ganglion (DRG) neurons were prepared as pre-
viously described (Vellani et al., 2004). Briefly, 20e30 ganglia were
isolated, incubated in collagenase (2.5mg ml1) for 1hourat 37 C
and mechanically triturated with a 45 mm sterile needle. The cell
suspension was filtered in 70 mm Nylon filter (BD Falcon) then
centrifuged and re-suspended in Dulbecco's modified Eagle's me-
dium (DMEM, Gibco) supplemented with 50 u ml1 penicillin and
0.05mg/ml streptomycin (Invitrogen), 1% L-glutamine (Invitrogen),
10% fetal bovine serum (FBS, Gibco), 50 ng/ml nerve growth factor
(NGF, Promega) and 1.25 mg/ml cytosine b-D-arabinofuranoside
(Ara-C, Sigma). DRG neurons were plated onto 13mm borosilicate
cover glass previously coated with polyL-lysine (100 mg ml1,
Sigma) and laminin (10 mg/ml, Sigma). The medium was changed
after 24 h. All electrophysiology recordings were made within 48 h
from dissociation. DRG neurons were classified based on diameter
of somata as follows: small (<25 mm), medium (25e35 mm) and
large (>35 mm).
2.8. Whole-cell patch clamp recordings
Voltage clamp experiments were performed using a PC-505B
amplifier (Warner, Handen, CT, USA) and digitalized with a Dig-
idata 1440 A and Clampex 10 (Axon, Sunnyvale, CA, USA). Pipettes,
resistance 3e4.5MU, were pulled from borosilicate capillaries
(Harvard Apparatus, London, UK) using a Narishige PP830 vertical
puller (Narishige International Ltd, London, UK). Access resistance
was monitored during whole-cell voltage clamp recordings
throughout experiments with short, 10mV steps. Recordings
undergoing 10% drift in access resistance were discarded. Pipette
capacitance transients were cancelled while no whole-cell
compensation was used. Signals were sampled at 10 kHz, low-
pass filtered at 1 kHz. All recordings were made at 21e22 C. Ih
was activated with a two-step protocol, consisting of a sequence of
hyperpolarizing voltage steps (1 s) from 50 to 140mV, followed
by a step at 140 mv (holding potential 60mV). Ih activation
curves were obtained plotting the Ih tail currents against each
imposed potential and were fitted with a Boltzmann equation of
the following form:
It / It (max) ¼ 1 / 1 þ exp [(Vm - V½) / k]
Where Vm is the membrane potential, V1/2 is the membrane
potential at which Ih is at half-maximal activation, k is the slope
factor, It is the current amplitude of the tail current recorded for a
given pre-pulse and It (max) is the maximum current amplitude of
the tail current. Ih current rate of activation in small neurons we fit
the current trace with a double exponential function the time
constant (s) of Ih activationwas determined by fitting currents with
a double exponential function as described previously (Yao et al.,
2003): Ih(t)¼ Af exp (-t/tf) þ As exp (-t/ts). The activation curve
was obtained from the tail current amplitude and the conductance
(G) at each step voltage was normalized to the conductanceat 130mV (Gmax) as previously reported (Cheng and Zhou, 2013).
Extracellular solution contained (in mM): 140 NaCl, 2 CaCl2, 1
MgCl2, 3 KCl, 10 HEPES, 10 D (þ) glucose, adjusted to pH 7.3 with
NaOH, osmolarity 300e310 mosmol/l. Pipette were filled with an
intracellular solution containing (in mM): 140 K þ -gluconate, 10
HEPES, 5 EGTA, 2 MgCl2, 5 Na2Pcreatine, 0.3 NaGTP, 2 MgATP and
adjusted to pH 7.3 with KOH, osmolarity 310e315 mosmol/l. Cells
were continuously perfused with extracellular solution using
gravity-fed perfusion system. All substances were dissolved in
water to obtain 1000-fold stock solutions prior to use.2.9. Western blot
Western blot (WB) analysis of DRGs was performed as previ-
ously reported (Laurino et al., 2015). Briefly, ganglia were isolated
from the full length of the spinal column and homogenised in a
buffer containing Tris HCl pH 8 50mM, NaCl 150mM, EDTA 1mM,
SDS 0,1% p/v and a Protease and Phosphatase Inhibitor Cocktail
(Thermo Scientific, Monza, Italy). Proteins (20 mg) isolated from
DRG were separated on 8% or 10% SDS-PAGE and transferred into
PVDF membranes (60min at 398mA) using standard procedures.
Blots were incubated overnight at 4 C with specific antibody
against HCN1, HCN2, HCN3, HCN4, KCNE2 (MiRP1) (Alomone Labs,
Israel) and a-tubulin (clone DM1A, cn 05e829, Merck Millipore,
Vimodrone, Milano) as reference protein. Primary antibodies were
diluted in PBS containing 3% albumin and 0.05% Tween. The anti-
geneantibody complexes were visualized using appropriate sec-
ondary antibodies (1:10 000, diluted in PBS containing 3% albumin
and 0.05% tween) and left for 1hourat room temperature. Blots
were then extensively washed and developed using an enhanced
chemiluminescence detection system (Pierce, Rodano, Italy).
Exposure and developing time were standardized for all blots.
Densitometry of scanned images was performed on a Macintosh
iMac computer using the public domain NIH Image program. Re-
sults represent mean± SEM of three different gels and they are
expressed as arbitrary units (AU), consisting of the ratio between
the expression levels of the protein of interest and of a-tubulin.2.10. Immunofluorescence
DRGs were isolated from the full length of the spinal column
following removal of the spinal cord and fixed in 4% para-
formaldehyde for 24 h and then cryo-embedded in Surgipath FSC22
(Leica Biosystems, USA). DRGs from 3 vehicle-treated and 3 OXA-
treated rats were sectioned at 10 mm thickness and processed for
immunofluorescence staining as previously described (Smith et al.,
2015). Primary antibodies (Alomone Laboratories, Israel) were used
as follows: HCN1, 1:1000; HCN2, 1:200; MiRP1, 1:50. Anti-rabbit
Alexa Fluor 568 (1:400, Life Technologies) was used as a second-
ary antibody. Sections were counterstained with DAPI (Roche) and
mounted in Prolong Gold (Life Technologies). All images were ac-
quired with identical settings with a 20X objective (0.5NA, PL APO
Fluotar), using a Leica DM6000B microscope equipped with a
DFC350FX camera (Leica Microsystems). Image analysis was per-
formed using Fiji-ImageJ (Schindelin et al., 2012) as follows: for
each cell analysed the maximum diameter and the mean fluores-
cence intensity were measured. DRGs were then classified as small
(diameter <25 mm), medium (diameter between 25 and 35 mm) and
large (diameter >35 mm) and themean fluorescence intensity in the
3 DRGs groups was statistically analysed by 2-way ANOVA with
Bonferroni correction for multiple comparisons, using Graphpad
Prism software.
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The frequency of the pulsations of caudal artery was determined
daily in conscious restrained rats by tail-cuff plethysmography. The
instrument used was a BP2000 blood pressure analysis system
designed and built by John E. Rogers and James P. Rogers (Visitech
Systems, Inc, Apex, NC). This system measures the heart rate,
expressed as beats per minute (bpm), with the use of an optical
sensor. Before the beginning of the experiments, rats were condi-
tioned one week to the procedure and manipulation. After habit-
uation to the tail cuff apparatus and stabilization of the heart rate,
each group of animals (CTRL and OXA) were treated with oral
administration of IVA (5mg/kg) and MEL57A (30mg/kg). Mea-
surements were repeated at 30, 60, 120 and 180min after IVA
administration and at 15, 30, 45 and 60min for MEL57A.
2.12. Data presentation and statistical analyses
Results are expressed as means± S.E.M. All datasets were tested
for approximation to a normal distribution with a D'Agostino test
(Graphpad Prism). Datasets were then analysed using parametric
statistical tests, t-test for single comparisons or two-way analysis of
variance [ANOVA] with Bonferroni post-hoc correction for multiple
comparisons, and non-parametric Fisher exact test. Mean differ-
ences were considered significant for p < .05 (*); p < .01 (**);
p < .001 (***). Data were analysed using Origin 9 software (Ori-
ginLab, Northampton, USA). Electrophysiological recordings, as
well as WB panels and immunofluorescence microscopic imagesFig. 1. Ih current gain of function in primary sensory neurons cultured from OXA-treated r
OXA-treated animals (OXA). B. Comparison of Ih current density among small, medium and
medium and large size DRG neurons. Inset, dot plot of V1/2 values in CTRL and OXA neuro
positive neurons, as assessed by determining the percentage of neurons expressing the t
to 90mV in small neurons from CTRL and OXA neurons to highlight the different activatishown in figures are intended to represent typical observations.
3. Results
3.1. Ih gain of function in DRG neurons from OXA-treated rats
We used standard patch clamp electrophysiology to charac-
terize the properties of Ih current in dissociated DRG neurons from
control (CTRL) and OXA-treated rats (OXA). We classified DRG
neurons by cell body diameter as large (>35 mm), medium (<35 mm)
and small (<25 mm), according to the literature (Harper and
Lawson, 1985), and measured the capacitance, resistance and
rheobase of the three categories. We observed that the passive
membrane properties did not change following OXA treatment
(SIA-B). The neuron-size classification allowed us to discriminate C
and Ad nociceptive fibers, represented by small and medium size
neurons, from non-nociceptive Ab fibers represented by large
neurons (Emery et al., 2011; Harper and Lawson, 1985; Momin
et al., 2008). On these premises, we first studied the amplitude of
Ih current in DRG neurons from CTRL and OXA groups. Results are
schematized in Fig.1, while complete numerical values are reported
in Table 1. We found that Ih current density was significantly
increased in small- and medium-size OXA neurons (Fig. 1A and B).
In contrast, the difference in Ih current density between large-size
(non-nociceptive) neurons from the two groups did not achieve
statistical significance (Fig. 1B, bottom). These results indicate a
sizeable gain of function of Ih in putative nociceptive neurons. A
similar OXA-induced increase in Ih current density was also seen inats. A. Ih current traces in small neurons of dissociated DRGs from control (CTRL) and
large size DRG neurons of the two groups. C. Voltage dependence of Ih current in small,
ns. D. DRG neurons from CTRL and OXA animals have a comparable percentage of Ih-
ypical “voltage sag” (top). E. Top, superimposed current traces obtained with a step
on kinetics. Bottom, dot plot showing tfast e tslow of Ih activation (test step¼90mV).
Table 1
Ih properties of small, medium and large neurons cultured in presence of NGF.
Neuron class Ih properties CTRL (n) OXA (n) p values e test (p)
Small density (pA/pF) 3.12± 0.63 (10) 6.98± 1.20 (11) 2,5E-5 -2 way ANOVA (6,2E-5)
V1/2 (mV) 100.02± 1.69 (10) 95.22± 0.80 (11) .024 - Unpaired t-test
Medium density (pA/pF) 2.77± 0.61 (11) 8.70± 2.11 (12) .021 - 2 way ANOVA (0.016)
V1/2 (mV) 91.36± 0.89 (10) 86.60± 0.51 (11) 6E-4 - Unpaired t-test
Large density (pA/pF) 9.62± 3.03 (10) 10.03± 1.95 (7) .201 - 2 way ANOVA (0.20)
V1/2 (mV) 89.88± 1.10 (10) 92.70± 0.50 (8) .098 - Unpaired t-test
Results are expressed as means± S.E.M.
Current density values are reported at the test step of 130mV.
Table 2
I h properties of small, medium and large neurons cultured in absence of NGF.
Neuron class Ih properties CTRL (n) OXA (n) p values e test (p)
Small density (pA/pF) 3,34± 1,68 (10) 7,75± 1,72 (11) 2.3 E-4 e 2 way ANOVA (9.2 E-4)
V1/2 (mV) 98,36± 2,60 (10) 86,37± 2,27(11) 3.2 E-5 - Unpaired t-test
Medium density (pA/pF) 2.52± 1.4(10) 8.23± 3.45(10) 4.4 E-3 -2 way ANOVA (0.004)
V1/2 (mV) 95,01± 1.96(10) 83,76± 0,55(10) 8 E-4 - Unpaired t-test
Large density (pA/pF) 10.65±4.69(10) 13.04± 4.92(10) .997 -2 way ANOVA (0.965)
V1/2 (mV) 85.22± 1.00(10) 85.29± 0.5(10) .950 - Unpaired t-test
Results are expressed as means ± S.E.M.
Current density values are reported at the test step of 130mV.
Fig. 2. Expression of HCN subunits in intact DRGs from CTRL and OXA animals. A. WB
experiment showing HCN1 (left), HCN2 (right) and respective a-tubulin signals. B.
Densitometry of HCN1 (left) and HCN2 (right) protein levels expressed as HCN/a-
tubulin signal intensity. Bar graphs represents mean ± SEM of 3 different experiments,
n¼ 6 for each group.
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medium (Table 2). We then tested the hypothesis that the bio-
physical properties of HCN channels were also altered in OXA
neurons. To this end, we performed a standard two-step voltage
clamp protocol and calculated activation curves from tail currents
(DiFrancesco et al., 1986). The half-activation value (V1/2) was
extrapolated from activation curves and used to compare experi-
mental groups. As shown in Fig. 1C, V1/2 in small and medium-size
neurons was significantly shifted towards depolarized potentials in
the OXA group. Interestingly, only a non-significant trend to V1/2
depolarization is seen in large neurons (1C, bottom). These results
indicate a significant increase of the open probability of the HCN
channels at physiological potential in nociceptive neurons causedby in vivo OXA treatment. We thenmeasured the activation kinetics
of Ih in small neurons to uncover potential alterations in the bio-
physical properties of HCN channels. To this aim, we fitted current
traces obtained at 90mV with a double exponential function (see
method), obtaining a fast and a slow time constant (tf, ts) near the
V½ potential (Fig. 1D). In agreement with the rightward shift in the
activation curve, the kinetics of Ih activationwas accelerated in OXA
neurons (tf, CTRL, 187.3± 54.7ms; OXA, 74.7± 10.1ms; n¼ 10,
p< .05. ts; CTRL, 831.1± 195,7ms; OXA, 483.4± 108.9ms; n¼ 10,
p< .05). Moreover, we observed that there was no significant dif-
ference in the number of small DRG neurons showing Ih current, by
estimating the percentage of neurons expressing a “voltage sag”
equal to, or greater than 10% of the total voltage rebound elicited by
a 200 pA hyperpolarizing current step (Emery et al., 2011). We
recorded from 20/29 small CTRL neurons and 28/33 OXA neurons
showing functional Ih (p> .05 Fisher's exact test, Fig. 1E). It was
previously reported that Ih affects the resting membrane potentials
(Biel et al., 2009; Dunlop et al., 2009; Pape, 1996). In our experi-
mental paradigm, we observed a trend to depolarization of the RMP
in OXA neurons (CTRL -52.12± 1.22mV n¼ 12; OXA
-48.72± 2.17mV n¼ 12; p> .05). In summary, patch clamp analysis
on dissociated DRG neurons indicates that small and medium
neurons from OXA-treated animals show an electrophysiological
profile dominated by a gain of function of Ih, which seems to
depend on increased channel expression and/or altered biophysical
properties.3.2. OXA-induced neuropathy reduces HCN2 expression in DRG
neruons
HCN1 and HCN2 are the most strongly expressed isoforms in
DRG neurons (Emery et al., 2011; Momin et al., 2008). However,
OXA-induced neuropathy might cause aberrant enhancement of
HCN 3 and 4, which are normally poorly expressed in this tissue.
Therefore, we performedWestern Blot analysis of all isoforms with
protein extracts from intact DRGs (Fig. 2A). We observed no sig-
nificant alteration in the expression of HCN1 (CTRL, 1.01± 0.15;
OXA, 0.86± 0.07 AU; n¼ 6; p> .05; Fig. 2A). Strikingly, HCN2 pro-
tein levels were reduced twofold in OXA rats compared to CTRL
(CTRL, 0.97± 0.19; OXA, 0.54± 0.2 AU; n¼ 6; p< .01; Fig. 2B). HCN3
F. Resta et al. / Neuropharmacology 131 (2018) 403e413408and 4 protein levels were very low in basal conditions showing
either no change or even slightly reduced expression level,
respectively (SII). In summary, WB analysis indicates that Ih gain of
function does not depend on overall increased expression of HCN
channels.
3.3. OXA-induced neuropathy increases the expression of MiRP1 in
large, medium and small neurons
In the attempt to explain the paradoxical increase in Ih current
density in the absence of an increase of HCN protein levels, we
studied the expression of the ancillary subunit MiRP1, previously
reported to boost HCN1 activation kinetics without affecting the
protein expression (Brandt et al., 2009). Interestingly, we observed
a significantly increased expression of MiRP1 in DRGs from OXA
rats (CTRL, 0.96± 0.08; OXA, 1.26± 0.15 AU; n¼ 6; p< .05; Fig. 3A).
In order to elucidate whether the elevation of MiRP1 expression
was differential among distinct DRG neuron subsets, we performed
immunofluorescence analysis on histological sections in intact
DRGs from the two experimental groups (Fig. 3B).We observed that
MiRP1 expression was increased of ~40% in all classes of DRG
neurons (Fig. 3A and B bottom). This result is consistent with the
increased current density and the enhanced gating kinetics that we
observed in small and medium neurons from OXA-treated rats.
3.4. Anti-hyperalgesic efficacy of pan HCN blockers in an animal
model of CIPN
Two weeks of chronic OXA administration (i.p., 2.4 mg/kg daily)
in rats induces a progressive peripheral neuropathy recapitulating
the peripheral painful state experienced by patients under OXAFig. 3. Expression of MiRP1 subunit in intact DRGs from CTRL and OXA animals. A. Top, W
protein levels expressed as MiRP1/a-tubulin signal intensity. Bar graphs represent mean± SE
sections from intact CTRL (left) and OXA (right) DRGs immunostained for MiRP1 (red) and D
box) and OXA (red box) DRGs (scale bar: 25 mm). C. Number of positive/negative neurons re
exact test). (For interpretation of the references to colour in this figure legend, the readerchemotherapy, which is characterized by mechanical and thermal
hypersensitivity. The entity of noxious and non-noxious mechani-
cal stimulus transmission, as well as the hypersensitivity to noxious
thermal stimuli characterizing OXA-induced peripheral neuropa-
thy, were measured with the paw pressure, the von Frey test and
the plantar test, respectively. On day 14, the weight tolerated on
posterior paws by OXA animals (paw pressure test) decreased from
64.4 ± 1.6 g (vehicle þ vehicle) to 42.9 ± 1.0 g (OXA þ vehicle,
p < .01 vs vehicle þ vehicle) (Fig. 4B, top, left). Subcutaneous (s.c)
injections of IVA at increasing doses (0.1e5mg/kg), reduced me-
chanical hypersensitivity. Of note, the anti-hyperalgesic effect of
IVAwas dose dependent (Fig. 4B, bottom). The effect of 5mg/kg IVA
started 30min after administration (56.4± 0.7 g) and peaked at
60min (59.4± 0.6 g). The anti-hypersensitivity effect was still sig-
nificant 120min after treatment (50.5± 1.5 g, p< .01) vanishing at
180min (45.0± 1.4 g). One mg/kg IVA showed the same long-
lasting effect, with the strongest anti-hyperalgesic effect recorded
120min after administration (56.4± 0.5 g, p< .05). The 0.1mg/kg
dose was ineffective (Fig. 4B top, left). In Fig. 4B, the withdrawal
threshold to non-noxious mechanical stimulus is shown. von Frey
test highlighted a decreased pain threshold at day 14 after OXA
treatment (OXA þ vehicle, 11.4 ± 0.3 g; vehicle þ vehicle,
22.3 ± 0.6 g). Both 1 and 5 mg/kg IVA were able to significantly
increase the withdrawal threshold of the animals starting 30 min
after injection (19.6 ± 0.3 g, p < .01 and 17.0 ± 0.2 g, p < .01,
respectively) and to reverse OXA-induced neuropathy after 60 min
(23.7 ± 0.7 g, p < .01 and 22.1 ± 1.5 g, p < .01, respectively; Fig. 4B,
top, middle). This effect lasted until 120min after injection. IVA
0.1mg/kg had no effect. Furthermore, acute IVA administrationwas
able to counteract OXA-induced thermal hyperalgesia (plantar
test). In this test, IVA (1e5mg/kg) increased the licking latency in aB experiment showing MiRP1 and a-tubulin signals. Bottom, densitometry of MiRP1
M of 3 different experiments (n¼ 6 for each group). B. Top, Microphotographs of 10 mm
API (blue; scale bar, 50 mm). Bottom, magnifications of selected areas from CTRL (green
presented as % of positive neuron in CTRL and OXA groups (statistical analysis: Fisher
is referred to the Web version of this article.)
Fig. 4. Anti-hyperalgesic effects of pan HCN blockers. A. Schematic of in vivo experimental protocol. Animals were treated with increasing doses of ZD7288 (ZD) and IVA. After-
wards, animal behaviour was monitored for 180min. B. Top, anti-hyperalgesic effects of ZD7288 in the paw pressure, von Frey and plantar tests. Bottom, anti-hyperalgesic effects of
IVA in thepaw pressure, von Frey and plantar tests.
F. Resta et al. / Neuropharmacology 131 (2018) 403e413 409dose-dependent manner with the highest efficacy reached by the
5mg/kg dose (Fig. 4B top, right). The anti-hypersensitivity effect
evoked by IVA treatment was significant from 30 until 120 min
while the lower (0.1 mg/kg) dose was ineffective. IVA 5 mg/kg of
administered in vehicle þ vehicle group did not alter the pain
threshold in control animals. For sake of comparison, we also tested
the effect of another pan HCN blocker, ZD7288, which has been
proved to exert anti-hypersensitivity effects in neuropathic pain
models (Lee et al., 2005; Smith et al., 2015) (Fig. 4B, top). Acute i.p.
treatment with the highest dose (10mg/kg) reduced the mechan-
ical hyperalgesia from 60min after injection while the dose of
1mg/kg induced a significant anti-hyperalgesic effect starting from
30min. Both dosages were effective until 120min after injection.
The lower dose was ineffective at all time points (Fig. 4B, bottom,
left). von Frey and plantar tests showed similar results (Fig. 4B
bottom, middle and right). Moreover, ZD 10mg/kg did not alter the
nociceptive response in control animals.
3.5. Selective HCN1 block is sufficient to revert OXA-induced
hyperalgesia
MEL57A is an IVA derivative recently developed by Romanelli
and collaborators, with EC50¼ 0.32± 0.06 mM for HCN1 and
75.26± 14.38 mM for HCN4 in transfected HEK293 cells (Melchiorre
et al., 2010; Del Lungo et al., 2012). We tested the efficacy of the
compound on Ih current in OXA neurons, in which the HCN1
component is predominant. We observed that MEL57A (30 mM)reduced Ih current amplitude bymore than 50% in 10min, the same
time required by IVA and ZD7288 (Masi et al., 2015; Resta et al.,
2016). As shown in Fig. 5B, normalized Ih conductance
at 100mV was significantly reduced in OXA neurons by MEL57A
(CTRL, 0.67± 0.08; OXA, 0.33± 0.25; n¼ 5, p< .05). We then tested
the ability of MEL57A to reduce hyperalgesia in neuropathic rats
(Fig. 5C). MEL57A 1mg/kg administered orally, significantly
relieved mechanical hypersensitivity at 15min (52.5± 1.2 g;
p< .01). This effect peaked at 30min (55.0± 0.9 g; p< .01) and
vanished 45min after treatment (47.9± 1.5 g). 10mg/kg was able to
reverse OXA neuropathy from 15 to 30min after treatment
(60.7± 1.3 g; p< .01 and 63.3± 0.8 g; p< .01, respectively). Anti-
hyperalgesic efficacy was still significant at 45min (52.4± 1.8 g;
p< .01), while disappearing at 60min (43.6± 1.5 g). The lower dose
was ineffective (Fig. 5C left panel). Similar results were obtained
with von Frey and plantar tests (Fig. 5C middle and right panels). In
summary, administration of MEL57A was able to relieve both me-
chanical and thermal hypersensitivity induced by OXA in a dose
dependentmanner reverting the neuropathic symptoms from 30 to
45min after the administration of the higher dose (Fig. 5C). 10mg/
kg MEL57A did not alter the nociceptive response in control
animals.
3.6. MEL57A and IVA have similar anti-hyperalgesic efficacy, but
MEL57A has no effects on heart rhythm
We assessed the anti-hyperalgesic efficacy of MEL57A relative to
Fig. 5. Selective block of HCN1 by MEL57A reduced HCN channels conductance in vitro and induced anti-hyperalgesic effect in vivo. A. Ih current traces recorded in a small OXA
neuron, before and 10min after application of MEL57A. Green traces indicate the test step to 100mV. B. Dot plot showing the effect of MEL57A on the HCN channels conductance.
Inset, bar graph showing the percentage of open HCN channels at 100mV. C. Top, schematic of in vivo experimental protocol. Bottom, anti-hyperalgesic effects of MEL57A in the
paw pressure, von Frey and plantar tests. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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test. We observed no significant differences in both the von Frey
test (MEL57A, 22.1± 1.5 s; IVA, 23.7± 0.7 s; p> .05) and the plantar
test (MEL57A, 16.8± 0.8 s; IVA, 17.3± 0.3 s; p> .05). Remarkably,
MEL57A performed better than IVA in the paw pressure test
(MEL57A, 63.3± 0.8 s; IVA, 59.4± 0.6 s; p< .01). These results sug-
gest a similar anti-hyperalgesic efficacy reached by the selective
block of HCN1, confirming the critical role of this HCN isoform in
maintaining the peripheral neuropathy caused by OXA adminis-
tration. A requirement for every drug designed to target Ih in pe-
ripheral neurons is to avoid or minimize the undesired effects
resulting from inhibition of HCN isoforms expressed in the
myocardium (Postea and Biel, 2011). CTRL and OXA rats received a
single subcutaneous injection of MEL57A and IVA, each at the dose
showing highest anti-hyperalgesic efficacy (10 and 5mg/kg,
respectively). As shown in Fig. 6, IV A significantly reduced the
heart rhythm in both CTRL (t0¼ 343± 21 bpm; t60¼ 273± 11 bpm;
n¼ 6, p< .01, t0 vs t60) and OXA rats (t0¼ 386± 18 bpm,
t60¼ 307± 14 bpm; n¼ 6, p< .05, t0 vs t60; t120¼ 293± 25 bpm;
n¼ 6, p< .01, t0 vs t120). On the contrary, we did not observe
changes in the heart rate following administration of the highest
MEL57A dose in CTRL (t0¼ 376± 25 bpm, t60¼ 368 ± 16 bpm;
n¼ 6, p> .05; t0 vs t60) or in OXA rats (t0¼ 370± 26 bpm,
t60¼ 376± 29 bpm; n¼ 6, p> .05, t0 vs t60). These results confirm
that MEL57A, at the dose showing the highest anti-hyperalgesicefficacy in pain tests, does not block HCN channels in the SAN
and thus does not alter the heart rate in either CTRL or OXA rats
(Fig. 6).
4. Discussion
4.1. CIPN is accompanied by HCN1 gain of function
In this study we used an animal model of CIPN described by
Cavaletti and collaborators in 2001 (Cavaletti et al., 2001). OXA
administration at 2.4mg/kg corresponds to the dosing employed in
cancer patients (considering the Km factor 37 for the conversion of
animal doses to the Human Equivalent Dose (Freireich et al., 1966;
Reagan-Shaw et al., 2008)). The daily repeated administration of
2.4mg/kg in the rat mimics the cumulative dosage of OXA even-
tually leading to chronic neuropathy in the clinical setting.
(Cavaletti et al., 2001). By using patch clamp electrophysiology in
dissociated DRG neurons from OXA rats we demonstrate that small
and medium neurons show a gain of function of Ih. Increased
current amplitude may result from increased channels expression
on the cell surface or enhanced conductance due to modification in
gating kinetics. By studying Ih voltage dependence, we observed a
rightward shift in the V1/2 as well as acceleration of activation ki-
netics in putative nociceptors. Therefore, we measured protein
levels of all HCN isoforms by western blot and observed a decrease
Fig. 6. Comparison between IVA (5mg/kg) and MEL57A (10mg/kg) for their anti-hyperalgesic efficacy and effect on the heart rate. A. Comparison of threshold values of IVA
(60min) and MEL57A (30min) in the paw pressure, von Frey and plantar tests (scatter graph, raw data). B. Heart rate was recorded for 180 min following administrations of IVA or
MEL57A in trained animals from both CTRL and OXA rats. A significant slowing of the heart rate was observed following administration of IVA in CTRL and OXA rats (blue circles). No
significant alterations of the heart rate were observed following MEL57A administrations (green circles). Statistical comparisons are made between OXA þ IVA and OXA þMEL57A.
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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modifications of HCN1 protein levels. HCN 3 and 4 were nearly
undetectable, as expected (Emery et al., 2011; Momin et al., 2008).
These results are different from what observed by Descoeur et al.
(2011). They found an increase in HCN1 mRNA without alteration
of HCN2 mRNA, in DRG from mice treated with a single i.p. in-
jections of OXA. In this regard, it must be noticed that our animal
model is deeply different, consisting in a chronic treatment (15
days). Moreover, it is possible that HCN1 mRNA is upregulated
while HCN1 protein is not, due to differential regulation at mRNA
and protein synthesis levels. The observed reduction of HCN2 iso-
form could determine an increased HCN1/HCN2 ratio, thus a
greater contribution of the HCN1-mediated component to global Ih
current. This could explain the right shift in V1/2 and the faster time
constant of activation observed in medium and small-size neurons.
In fact, HCN1 has the less negative V1/2 and the fastest gating ki-
netics (Biel et al., 2009). To understand how Ih density and acti-
vation could be sped up without an increased expression of HCN
channels, wemeasured the expression of the ion channel b-subunit
MiRP1, which has been reported to increase the conductance and
the activation kinetics of HCN channels (Abbott, 2012; Brandt et al.,
2009; Yu et al., 2001). In agreement, with immunofluorescence on
whole DRGs, we found elevated expression of MiRP1 in the DRG of
OXA rats. Although not sufficient to establish a cause-effect link, the
observed increase in MiRP1 expression may explain the OXA-
induced pathological alteration of Ih function. Further studies will
be needed to clarify themechanisms linking HCN1-driven Ih gain of
function to the alterations induced by chronic exposure to OXA.4.2. Selective block of HCN1 reduces neuropathy without cardiac
side effects
To study the role of the HCN gain of function on the expressionof neuropathy, we treated neuropathic animals with two different
pan HCN blocker, IVA and ZD7288, and found that both induce a
strong anti-hyperalgesic effect in mechanical and thermal pain
tests confirming the critical role of the HCN channels in sustaining
the transmission of neuropathic painful stimuli. However, to
exploit the therapeutic potential of HCN channel blockers, one
critical goal is to design isoform-specific compounds. New HCN
channels-targeted analgesic compounds should feature sufficient
selectivity for HCN1 or HCN2 over HCN4 channels expressed in
pace-making cells of sinus atrial node, which play a major role
during the diastolic depolarization phase of the heart rhythm. To
this aim, we tested the HCN1-selective blocker MEL57A, recently
developed by Romanelli and collaborators (Del Lungo et al., 2012;
Melchiorre et al., 2010). After confirming the capability of
MEL57A to reduce the HCN channels conductance in small DRG
neurons, we tested it in vivo in increasing doses to study its po-
tential anti-hyperalgesic effect. As expected, we observed that
MEL57A induced anti-hyperalgesic effect with a potency and effi-
cacy similar to IVA. Importantly, we compared the highest pain
threshold of neuropathic animals following administration of IVA
and MEL57A, observing no significant differences except for the
paw pressure test, in which MEL57A seems to possess higher effi-
cacy. Due to the reduction in HCN2 expression, combined to the
overexpression of MiRP1, HCN1 component is expected to increase
in OXA neurons. Thus, selective block of HCN1 is apparently suffi-
cient to normalixe pathological excitability of OXA-treated noci-
ceptors, thus exerting an anti-hyperalgesic action, whose
effectiveness matches that afforded by non-selective HCN blockers.
The most important limitation to the use of IVA as an analgesic
medication is the depressive effect on heart rate, which is unde-
sirable in patients not suffering from angina (Postea and Biel, 2011).
In order to study the effects of MEL57A on heart rhythm, we
measured the heart rate of CTRL and OXA rats following acute
F. Resta et al. / Neuropharmacology 131 (2018) 403e413412administration of IVA and MEL57A, and found that MEL57A is
devoid of bradycardic action in both groups. This finding is of great
relevance in view of the future clinical use of this one, or other
HCN1 selective blockers. In summary, this work proposes a mo-
lecular mechanism explaining the paradoxical Ih gain of function,
in the absence of overall HCN protein upregulation, characterizing
neuropathic DRG neurons, and provides pharmacological evidence
for a prominent role of HCN1 in CIPN. Importantly, the reported
dysfunction of HCN1 channels is disease specific. This is a critical
aspect towards the development of drugs with optimal efficacy and
safety profile. Consistently, we found that selective HCN1 block has
an effective and safe analgesic action in preclinical models of
neuropathic pain. Interestingly, HCN1 gene expression increases in
DRG neurons after paclitaxel treatment (Zhang and Dougherty,
2014), suggesting that Ih gain of function may be envisioned as a
common pathogenic mechanism involved in the development of
neuropathic states induced by different chemotherapeutics. To
conclude, MEL57A, by selectively blocking HCN1 at peripheral level,
could represent a promising lead compound to further develop a
new generation of analgesic drugs to control different types of
CIPN.
Acknowledgments
This work was supported by a grant from the Ente Cassa di
Risparmio di Firenze (MANNECRF14; GM).
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.neuropharm.2018.01.014.
References
Abbott, G.W., 2012. KCNE2 and the K (þ) channel: the tail wagging the dog.
Channels (Austin) 6, 1e10.
Addington, J., Freimer, M., 2016. Chemotherapy-induced peripheral neuropathy: an
update on the current understanding. F1000Res 5.
Avan, A., Postma, T.J., Ceresa, C., Cavaletti, G., Giovannetti, E., Peters, G.J., 2015.
Platinum-induced neurotoxicity and preventive strategies: past, present, and
future. Oncologist 20, 411e432.
Berdeaux, A., Tissier, R., Couvreur, N., Salouage, I., Ghaleh, B., 2009. Heart rate
reduction: beneficial effects in heart failure and post-infarcted myocardium.
Therapie 64, 87e91.
Biel, M., Wahl-Schott, C., Michalakis, S., Zong, X., 2009. Hyperpolarization-activated
cation channels: from genes to function. Physiol. Rev. 89, 847e885.
Bokhari, F., Sawatzky, J.A., 2009. Chronic neuropathic pain in women after breast
cancer treatment. Pain Manag. Nurs. 10, 197e205.
Brandt, M.C., Endres-Becker, J., Zagidullin, N., Motloch, L.J., Er, F., Rottlaender, D.,
Michels, G., Herzig, S., Hoppe, U.C., 2009. Effects of KCNE2 on HCN isoforms:
distinct modulation of membrane expression and single channel properties.
Am. J. Physiol. Heart Circ. Physiol. 297, H355eH363.
Cavaletti, G., 2014. Chemotherapy-induced peripheral neurotoxicity (CIPN): what
we need and what we know. J. Peripher. Nerv. Syst. 19, 66e76.
Cavaletti, G., Tredici, G., Petruccioli, M.G., Donde, E., Tredici, P., Marmiroli, P.,
Minoia, C., Ronchi, A., Bayssas, M., Etienne, G.G., 2001. Effects of different
schedules of OXA treatment on the peripheral nervous system of the rat. Eur. J.
Canc. 37, 2457e2463.
Cheng, Q., Zhou, Y., 2013. Novel role of KT5720 on regulating hyperpolarization-
activated cyclic nucleotide-gated channel activity and dorsal root ganglion
neuron excitability. DNA Cell Biol. 32, 320e328.
Dalle, C., Eisenach, J.C., 2005. Peripheral block of the hyperpolarization-activated
cation current (Ih) reduces mechanical allodynia in animal models of post-
operative and neuropathic pain. Reg. Anesth. Pain Med. 30, 243e248.
Del Lungo, M., Melchiorre, M., Guandalini, L., Sartiani, L., Mugelli, A., Koncz, I.,
Szel, T., Varro, A., Romanelli, M.N., Cerbai, E., 2012. Novel blockers of
hyperpolarization-activated current with isoform selectivity in recombinant
cells and native tissue. Br. J. Pharmacol. 166, 602e616.
Descoeur, J., Pereira, V., Pizzoccaro, A., Francois, A., Ling, B., Maffre, V., Couette, B.,
Busserolles, J., Courteix, C., Noel, J., Lazdunski, M., Eschalier, A., Authier, N.,
Bourinet, E., 2011. OXA-induced cold hypersensitivity is due to remodelling of
ion channel expression in nociceptors. EMBO Mol. Med. 3, 266e278.
Di Cesare Mannelli, L., Pacini, A., Micheli, L., Femia, A.P., Maresca, M., Zanardelli, M.,
Vannacci, A., Gallo, E., Bilia, A.R., Caderni, G., Firenzuoli, F., Mugelli, A.,Ghelardini, C., 2017. Astragali radix: could it be an adjuvant for OXA-induced
neuropathy? Sci. Rep. 7, 42021.
DiFrancesco, D., Ferroni, A., Mazzanti, M., Tromba, C., 1986. Properties of the
hyperpolarizing-activated current (if) in cells isolated from the rabbit sino-
atrial node. J. Physiol. 377, 61e88.
Dunlop, J., Vasilyev, D., Lu, P., Cummons, T., Bowlby, M.R., 2009. Hyperpolarization-
activated cyclic nucleotide-gated (HCN) channels and pain. Curr. Pharmaceut.
Des. 15, 1767e1772.
Emery, E.C., Young, G.T., Berrocoso, E.M., Chen, L., McNaughton, P.A., 2011. HCN2 ion
channels play a central role in inflammatory and neuropathic pain. Science 333,
1462e1466.
Freireich, E.J., Gehan, E.A., Rall, D.P., Schmidt, L.H., Skipper, H.E., 1966. Quantitative
comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, mon-
key, and man. Cancer Chemother. Rep. 50, 219e244.
Harper, A.A., Lawson, S.N., 1985. Conduction velocity is related to morphological cell
type in rat dorsal root ganglion neurones. J. Physiol. 359, 31e46.
Jiang, Y.Q., Xing, G.G., Wang, S.L., Tu, H.Y., Chi, Y.N., Li, J., Liu, F.Y., Han, J.S., Wan, Y.,
2008. Axonal accumulation of hyperpolarization-activated cyclic nucleotide-
gated cation channels contributes to mechanical allodynia after peripheral
nerve injury in rat. Pain 137, 495e506.
Kim, J.H., Dougherty, P.M., Abdi, S., 2015. Basic science and clinical management of
painful and non-painful chemotherapy-related neuropathy. Gynecol. Oncol.
136, 453e459.
Laurino, A., De Siena, G., Resta, F., Masi, A., Musilli, C., Zucchi, R., Raimondi, L., 2015.
3-iodothyroacetic acid, a metabolite of thyroid hormone, induces itch and re-
duces threshold to noxious and to painful heat stimuli in mice. Br. J. Pharmacol.
172, 1859e1868.
Lee, D.H., Chang, L., Sorkin, L.S., Chaplan, S.R., 2005. Hyperpolarization-activated,
cation-nonselective, cyclic nucleotide-modulated channel blockade alleviates
mechanical allodynia and suppresses ectopic discharge in spinal nerve ligated
rats. J. Pain 6, 417e424.
Masi, A., Narducci, R., Resta, F., Carbone, C., Kobayashi, K., Mannaioni, G., 2015.
Differential contribution of Ih to the integration of excitatory synaptic inputs in
substantia nigra pars compacta and ventral tegmental area dopaminergic
neurons. Eur. J. Neurosci. 42 (9), 2699e2706.
McGrath, J.C., Lilley, E., 2015. Implementing guidelines on reporting research using
animals (ARRIVE etc.): new requirements for publication in BJP. Br. J. Pharmacol.
172, 3189e3193.
Melchiorre, M., Del Lungo, M., Guandalini, L., Martini, E., Dei, S., Manetti, D.,
Scapecchi, S., Teodori, E., Sartiani, L., Mugelli, A., Cerbai, E., Romanelli, M.N.,
2010. Design, synthesis, and preliminary biological evaluation of new isoform-
selective f-current blockers. J. Med. Chem. 53, 6773e6777.
Momin, A., Cadiou, H., Mason, A., McNaughton, P.A., 2008. Role of the
hyperpolarization-activated current Ih in somatosensory neurons. J. Physiol.
586, 5911e5929.
Novella Romanelli, M., Sartiani, L., Masi, A., Mannaioni, G., Manetti, D., Mugelli, A.,
Cerbai, E., 2016. HCN channels modulators: the need for selectivity. Curr. Top.
Med. Chem. 16, 1764e1791.
Pape, H.C., 1996. Queer current and pacemaker: the hyperpolarization-activated
cation current in neurons. Annu. Rev. Physiol. 58, 299e327.
Postea, O., Biel, M., 2011. Exploring HCN channels as novel drug targets. Nat. Rev.
Drug Discov. 10, 903e914.
Reagan-Shaw, S., Nihal, M., Ahmad, N., 2008. Dose translation from animal to hu-
man studies revisited. Faseb. J. 22, 659e661.
Resta, F., Masi, A., Sili, M., Laurino, A., Moroni, F., Mannaioni, G., 2016. Kynurenic acid
and zaprinast induce analgesia by modulating HCN channels through GPR35
activation. Neuropharmacology 108, 136e143.
Roberts, J.A., Jenison, E.L., Kim, K., Clarke-Pearson, D., Langleben, A., 1997.
A randomized, multicenter, double-blind, placebo-controlled, dose-finding
study of ORG 2766 in the prevention or delay of cisplatin-induced neuropa-
thies in women with ovarian cancer. Gynecol. Oncol. 67, 172e177.
Sakurai, M., Egashira, N., Kawashiri, T., Yano, T., Ikesue, H., Oishi, R., 2009. OXA-
induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but
not mechanical allodynia. Pain 147, 165e174.
Sartiani, L., Mannaioni, G., Masi, A., Novella Romanelli, M., Cerbai, E., 2017. The
hyperpolarization-activated cyclic nucleotide-gatedc: from biophysics to phar-
macology of a unique family of ion channels. Pharmacol. Rev. 69, 354e395.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.Y., White, D.J.,
Hartenstein, V., Eliceiri, K., Tomancak, P., Cardona, A., 2012. Fiji: an open-source
platform for biological-image analysis. Nat. Med. 9, 676e682.
Smith, T., Al Otaibi, M., Sathish, J., Djouhri, L., 2015. Increased expression of HCN2
channel protein in L4 dorsal root ganglion neurons following axotomy of L5-
and inflammation of L4-spinal nerves in rats. Neuroscience 295, 90e102.
Stillitano, F., Lonardo, G., Giunti, G., Del Lungo, M., Coppini, R., Spinelli, V.,
Sartiani, L., Poggesi, C., Mugelli, A., Cerbai, E., 2013. Chronic atrial fibrillation
alters the functional properties of if in the human atrium. J. Cardiovasc. Elec-
trophysiol. 24, 1391e1400.
Takasu, K., Ono, H., Tanabe, M., 2010. Spinal hyperpolarization-activated cyclic
nucleotide-gated cation channels at primary afferent terminals contribute to
chronic pain. Pain 151, 87e96.
Tao, F., Tao, Y.X., Zhao, C., Dore, S., Liaw, W.J., Raja, S.N., Johns, R.A., 2004. Differential
roles of neuronal and endothelial nitric oxide synthases during carrageenan-
induced inflammatory hyperalgesia. Neuroscience 128, 421e430.
Vellani, V., Zachrisson, O., McNaughton, P.A., 2004. Functional bradykinin B1
F. Resta et al. / Neuropharmacology 131 (2018) 403e413 413receptors are expressed in nociceptive neurones and are upregulated by the
neurotrophin GDNF. J. Physiol. 560, 391e401.
Yao, H., Donnelly, D.F., Ma, C., LaMotte, R.H., 2003. Upregulation of the
hyperpolarization-activated cation current after chronic compression of the
dorsal root ganglion. J. Neurosci. 23, 2069e2074.
Young, G.T., Emery, E.C., Mooney, E.R., Tsantoulas, C., McNaughton, P.A., 2014. In-
flammatory and neuropathic pain are rapidly suppressed by peripheral block of
hyperpolarisation-activated cyclic nucleotide-gated ion channels. Pain 155,
1708e1719.Yu, H., Wu, J., Potapova, I., Wymore, R.T., Holmes, B., Zuckerman, J., Pan, Z., Wang, H.,
Shi, W., Robinson, R.B., El-Maghrabi, M.R., Benjamin, W., Dixon, J., McKinnon, D.,
Cohen, I.S., Wymore, R., 2001. MinK-related peptide 1: a beta subunit for the
HCN ion channel subunit family enhances expression and speeds activation.
Circ. Res. 88, E84eE87.
Zhang, H., Dougherty, P.M., 2014. Enhanced excitability of primary sensory neurons
and altered gene expression of neuronal ion channels in dorsal root ganglion in
paclitaxel-induced peripheral neuropathy. Anesthesiology 120, 1463e1475.
